Case discussion on bronchiectasis

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

bronchiectasis

Reading File
Finding Sources
Searching PubMed

bronchiectasis management

Searching Images

bronchiectasis HRCT chest CT scan signet ring

This diagnostic image is an axial slice from a Computed Tomography (CT) scan of the chest, displayed in a lung window. The primary finding is widespread cylindrical bronchiectasis, indicated by red arrows pointing to dilated, thick-walled bronchi. In cross-section, these dilated airways demonstrate the characteristic 'signet ring' sign, where the diameter of the bronchus is significantly larger than its accompanying pulmonary artery. The distribution of the bronchiectasis is bilateral and diffuse, involving multiple lobes. The background lung parenchyma exhibits heterogeneous areas of increased opacity and textural irregularity consistent with chronic inflammatory or post-infectious changes, though no acute pulmonary consolidation is visible. This imaging illustrates the typical morphological presentation of secondary bronchiectasis, often associated with chronic respiratory conditions or recurrent aspiration. The scan demonstrates the diagnostic utility of HRCT in evaluating airway dilation and bronchial wall thickening.

This diagnostic image is an axial slice from a Computed Tomography (CT) scan of the chest, displayed in a lung window. The primary finding is widespread cylindrical bronchiectasis, indicated by red arrows pointing to dilated, thick-walled bronchi. In cross-section, these dilated airways demonstrate the characteristic 'signet ring' sign, where the diameter of the bronchus is significantly larger than its accompanying pulmonary artery. The distribution of the bronchiectasis is bilateral and diffuse, involving multiple lobes. The background lung parenchyma exhibits heterogeneous areas of increased opacity and textural irregularity consistent with chronic inflammatory or post-infectious changes, though no acute pulmonary consolidation is visible. This imaging illustrates the typical morphological presentation of secondary bronchiectasis, often associated with chronic respiratory conditions or recurrent aspiration. The scan demonstrates the diagnostic utility of HRCT in evaluating airway dilation and bronchial wall thickening.

This diagnostic image is a thin-section high-resolution computed tomography (HRCT) axial reconstruction of the chest from a 15-year-old male with cystic fibrosis (CF). The image demonstrates severe bilateral bronchiectasis, characterized by significant bronchial dilatation. Multiple instances of the 'signet ring sign' are visible, where the internal diameter of the bronchus is larger than its accompanying pulmonary artery. There is a notable lack of normal bronchial tapering, with dilated airways extending into the lung periphery and visible within 1 cm of the pleural surface. The parenchyma shows mosaic attenuation; areas of decreased CT attenuation consistent with air trapping are observed in the central parenchyma, while regions marked with asterisks represent areas of relatively normal lung attenuation. The findings illustrate advanced chronic suppurative lung disease and small airway involvement common in pediatric CF patients with impaired pulmonary function (FEV1 45%).

This diagnostic image is a thin-section high-resolution computed tomography (HRCT) axial reconstruction of the chest from a 15-year-old male with cystic fibrosis (CF). The image demonstrates severe bilateral bronchiectasis, characterized by significant bronchial dilatation. Multiple instances of the 'signet ring sign' are visible, where the internal diameter of the bronchus is larger than its accompanying pulmonary artery. There is a notable lack of normal bronchial tapering, with dilated airways extending into the lung periphery and visible within 1 cm of the pleural surface. The parenchyma shows mosaic attenuation; areas of decreased CT attenuation consistent with air trapping are observed in the central parenchyma, while regions marked with asterisks represent areas of relatively normal lung attenuation. The findings illustrate advanced chronic suppurative lung disease and small airway involvement common in pediatric CF patients with impaired pulmonary function (FEV1 45%).

This diagnostic axial CT scan of the chest focuses on the lower lung parenchyma and mediastinal structures at the level of a vertebral body. The image primarily demonstrates the 'signet ring sign,' a hallmark radiological finding of bronchiectasis. Specifically, highlighted regions show pathological bronchial dilation where the internal diameter of the air-filled bronchus is significantly larger than its accompanying pulmonary artery. In a healthy lung, the bronchus-to-artery (BA) ratio is typically 1:1 or less; here, the enlarged, thin-walled bronchus (the ring) adjacent to the smaller, opaque circular artery (the signet) indicates airway disease. The surrounding lung parenchyma appears largely hypodense and air-filled, though multiple discrete BA pairs across both lung fields exhibit similar morphological changes. This visual is used to teach diagnostic criteria for chronic obstructive or inflammatory lung conditions, such as bronchiectasis, by illustrating the lack of normal airway tapering and disproportionate bronchial enlargement.

This diagnostic axial CT scan of the chest focuses on the lower lung parenchyma and mediastinal structures at the level of a vertebral body. The image primarily demonstrates the 'signet ring sign,' a hallmark radiological finding of bronchiectasis. Specifically, highlighted regions show pathological bronchial dilation where the internal diameter of the air-filled bronchus is significantly larger than its accompanying pulmonary artery. In a healthy lung, the bronchus-to-artery (BA) ratio is typically 1:1 or less; here, the enlarged, thin-walled bronchus (the ring) adjacent to the smaller, opaque circular artery (the signet) indicates airway disease. The surrounding lung parenchyma appears largely hypodense and air-filled, though multiple discrete BA pairs across both lung fields exhibit similar morphological changes. This visual is used to teach diagnostic criteria for chronic obstructive or inflammatory lung conditions, such as bronchiectasis, by illustrating the lack of normal airway tapering and disproportionate bronchial enlargement.

Reading File
Reading File
Reading File
Reading File
Reading File
Here is a comprehensive case discussion on bronchiectasis, drawing from Murray & Nadel's Textbook of Respiratory Medicine, Grainger & Allison's Diagnostic Radiology, and Robbins & Kumar Basic Pathology.

Bronchiectasis - Case Discussion

Definition

Bronchiectasis is the permanent, irreversible dilation of bronchi and bronchioles caused by destruction of the bronchial wall's smooth muscle and elastic tissue. It always occurs secondary to persistent infection or obstruction - it is not a primary disorder.

Etiology & Predisposing Conditions

CategoryExamples
Post-infectiousTB (major cause in endemic areas), Staphylococcus aureus, Klebsiella, pertussis, SARS-CoV-2
Bronchial obstructionTumors, foreign bodies, mucus impaction, atopic asthma
Congenital/HereditaryCystic fibrosis, primary ciliary dyskinesia (immotile cilia syndrome), Kartagener syndrome
ImmunodeficiencyHypogammaglobulinemia (recurrent bacterial infections)
Parenchymal fibrosisTraction bronchiectasis from fibrotic retraction

Pathogenesis

Two intertwined processes drive bronchiectasis - obstruction + chronic infection - forming a vicious cycle:
  1. Obstruction impairs secretion clearance → bacterial colonization
  2. Infection causes necrotizing inflammation → bronchial wall damage
  3. Cytokines, bacterial toxins, and proteases perpetuate the cycle
  4. Irreversible dilation and peribronchial fibrosis result
  • Robbins & Kumar Basic Pathology, p.455

Types (Pathological Classification)

By increasing severity:
  • Cylindrical - uniform, regular airway dilation (least severe)
  • Varicose - non-uniform, serpiginous ("beaded") dilation
  • Cystic/Saccular - most severe; string or cluster of cysts, often with air-fluid levels

Clinical Features

FeatureDescription
CoughChronic, productive - the most prominent symptom
Sputum≥30 mL/day of mucopurulent, sometimes foul-smelling sputum
HemoptysisCan range from blood-streaked sputum to massive bleed
DyspneaEspecially in extensive disease
RhinosinusitisCommon associated finding
SystemicFever, weight loss during exacerbations
Classic exam finding: Coarse crepitations on auscultation, finger clubbing in chronic disease.
Common sputum pathogens: Haemophilus influenzae, Pseudomonas aeruginosa, Staphylococcus aureus

Complications

  • Obstructive ventilatory defect with hypoxemia and hypercapnia
  • Cor pulmonale (pulmonary hypertension from chronic hypoxia)
  • Brain abscess (hematogenous spread)
  • Secondary amyloidosis (now rare with modern treatment)
  • Massive hemoptysis

Radiology

Chest X-Ray Signs

  • Tramlines - parallel line opacities (bronchial wall thickening seen in profile)
  • Ring opacities - bronchi seen end-on
  • Mucus plugs - tubular or ovoid opacities
  • Overinflation (in CF-associated bronchiectasis)
  • Atelectasis in affected segments

HRCT (Gold Standard)

Key signs:
  • Signet ring sign - bronchus diameter > adjacent pulmonary artery (most recognized sign)
  • Lack of normal bronchial tapering (the cardinal sign)
  • Bronchi visible within 1 cm of costal pleura (normally they are not)
  • Varicose pattern - beaded configuration
  • Cystic pattern - string/cluster of cysts, may have air-fluid levels
  • Mucus-filled dilated bronchi ("glove-finger" opacities)
  • Grainger & Allison's Diagnostic Radiology, p.155-156
Here are the characteristic HRCT findings:
Bilateral cylindrical bronchiectasis with signet ring sign on HRCT
HRCT showing bilateral cylindrical bronchiectasis with the classic signet ring sign (dilated bronchi larger than accompanying pulmonary arteries)
HRCT bronchiectasis in cystic fibrosis - severe bilateral disease
Severe bilateral bronchiectasis in cystic fibrosis - multiple signet ring signs with lack of bronchial tapering

Management

Airway Clearance (cornerstone of therapy)

  • Chest physiotherapy and postural drainage - essential in all patients
  • Active cycle of breathing techniques (ACBT)
  • Inhaled beta-2 agonists - improve mucociliary clearance and reverse bronchoconstriction

Antibiotics

  • Targeted at identified pathogens during exacerbations
  • Long-term macrolide therapy (e.g., azithromycin) - reduces exacerbation frequency and improves lung function in recurrent disease
  • Inhaled tobramycin for Pseudomonas-colonized patients: a 2025 meta-analysis (PMID: 40339664) confirmed benefit in non-CF bronchiectasis

Mucoactive Agents

DPP-1 Inhibitors (Emerging)

  • Brensocatib (DPP-1/dipeptidyl peptidase-1 inhibitor) reduces neutrophilic airway inflammation
  • A 2025 GRADE meta-analysis (PMID: 41299471) confirmed efficacy and safety in bronchiectasis - represents a newer disease-modifying approach

Surgical

  • Lobectomy/segmentectomy for localized disease refractory to medical therapy or causing massive hemoptysis
  • Lung transplantation in end-stage CF-related bronchiectasis

Antitussives

  • Not recommended in bronchiectasis - cough is the primary airway clearance mechanism

Key Points for Exam

PointDetail
Diagnostic gold standardHRCT chest
Most common morphologyCylindrical (least severe)
Most severe morphologyCystic/saccular
Most common lower lobe pathogenPseudomonas aeruginosa
Why antitussives are contraindicatedCough clears secretions - suppressing it worsens disease
CF-related bronchiectasis locationUpper lobes (unlike most other causes - lower lobes)
Pathological hallmarkIrreversible dilation beyond 4x normal diameter

Sources: Robbins & Kumar Basic Pathology (p.454-455), Murray & Nadel's Textbook of Respiratory Medicine (p.875), Grainger & Allison's Diagnostic Radiology (p.154-156)

Pulmonary hypertension case study

Reading File
Finding Sources
Searching PubMed

pulmonary arterial hypertension treatment

Searching Images

pulmonary hypertension plexiform lesion histology right heart catheterization

This composite educational image illustrates diagnostic modalities for Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Part A displays Right Heart Catheterization (RHC) hemodynamic waveforms and pressure readings. The pulmonary artery (PA) pressure (54/18/30 mmHg) and right ventricular (RV) pressure (51/6/10 mmHg) show significant systolic elevation, while the pulmonary capillary wedge pressure (PCWP 15/2/8 mmHg) remains within the normal range, confirming a precapillary pulmonary hypertension profile. Part B presents Digital Subtraction Angiography (DSA) of the bilateral pulmonary vasculature. A diagnostic catheter is seen traversing the right heart into the pulmonary arteries. The angiography reveals characteristic CTEPH findings, including irregular arterial branching, segmental stenoses, and 'pruned' distal vasculature, particularly evident on the left side. These visual features signify organized thrombi and microvasculopathy. This material is designed for advanced medical education in cardiology and pulmonology to demonstrate the integration of invasive hemodynamics and vascular imaging in the confirmatory diagnosis of Group 4 pulmonary hypertension.

This composite educational image illustrates diagnostic modalities for Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Part A displays Right Heart Catheterization (RHC) hemodynamic waveforms and pressure readings. The pulmonary artery (PA) pressure (54/18/30 mmHg) and right ventricular (RV) pressure (51/6/10 mmHg) show significant systolic elevation, while the pulmonary capillary wedge pressure (PCWP 15/2/8 mmHg) remains within the normal range, confirming a precapillary pulmonary hypertension profile. Part B presents Digital Subtraction Angiography (DSA) of the bilateral pulmonary vasculature. A diagnostic catheter is seen traversing the right heart into the pulmonary arteries. The angiography reveals characteristic CTEPH findings, including irregular arterial branching, segmental stenoses, and 'pruned' distal vasculature, particularly evident on the left side. These visual features signify organized thrombi and microvasculopathy. This material is designed for advanced medical education in cardiology and pulmonology to demonstrate the integration of invasive hemodynamics and vascular imaging in the confirmatory diagnosis of Group 4 pulmonary hypertension.

A multi-parameter medical monitor display from a right heart catheterization (RHC) procedure. The primary visual focus is a pulmonary artery (PA) pressure waveform tracing, which demonstrates significantly elevated pressures. The PA waveform shows cyclical systolic peaks (labeled 'S') and diastolic troughs (labeled 'D'), with a numerical measurement of 68/24 (38) mmHg, indicating pulmonary hypertension. Positioned above the PA tracing are three electrocardiogram (ECG) leads (II, III, and aVL) showing a sinus rhythm at a heart rate (HR) of 93 beats per minute. Below the pressure tracing are continuous waveforms for pulse oximetry (SpO2) and respiration (Resp). Numerical data at the bottom of the screen confirm a heart rate of 93 bpm, a respiratory rate of 16 inspirations per minute, and an oxygen saturation level of 93%. This clinical image illustrates hemodynamic monitoring in a patient with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) following medical management.

A multi-parameter medical monitor display from a right heart catheterization (RHC) procedure. The primary visual focus is a pulmonary artery (PA) pressure waveform tracing, which demonstrates significantly elevated pressures. The PA waveform shows cyclical systolic peaks (labeled 'S') and diastolic troughs (labeled 'D'), with a numerical measurement of 68/24 (38) mmHg, indicating pulmonary hypertension. Positioned above the PA tracing are three electrocardiogram (ECG) leads (II, III, and aVL) showing a sinus rhythm at a heart rate (HR) of 93 beats per minute. Below the pressure tracing are continuous waveforms for pulse oximetry (SpO2) and respiration (Resp). Numerical data at the bottom of the screen confirm a heart rate of 93 bpm, a respiratory rate of 16 inspirations per minute, and an oxygen saturation level of 93%. This clinical image illustrates hemodynamic monitoring in a patient with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) following medical management.

A diagnostic hemodynamic tracing from a right heart catheterization (RHC) procedure. The image displays synchronized multi-parameter monitoring data, including a three-lead electrocardiogram (ECG) at the top showing leads II, III, and aVL with a heart rate of 93 bpm. The central section features a pressure-volume waveform representing pulmonary artery (PA) pressures. Systolic peaks (S) are visualized reaching approximately 68-70 mmHg, and diastolic troughs (D) are noted at approximately 24 mmHg, indicating significant pulmonary hypertension. A concurrent flatter waveform represents the pulmonary capillary wedge pressure (PCWP), with a mean value indicated around 38 mmHg. Bottom panels display digital telemetry data including a plethysmographic oxygen saturation (SpO2) of 93% and a respiratory rate of 16 inspirations per minute (ipm). This tracing is used in clinical cardiology and pulmonology to evaluate pulmonary vascular resistance and hemodynamic response in patients with systemic sclerosis-associated pulmonary arterial hypertension.

A diagnostic hemodynamic tracing from a right heart catheterization (RHC) procedure. The image displays synchronized multi-parameter monitoring data, including a three-lead electrocardiogram (ECG) at the top showing leads II, III, and aVL with a heart rate of 93 bpm. The central section features a pressure-volume waveform representing pulmonary artery (PA) pressures. Systolic peaks (S) are visualized reaching approximately 68-70 mmHg, and diastolic troughs (D) are noted at approximately 24 mmHg, indicating significant pulmonary hypertension. A concurrent flatter waveform represents the pulmonary capillary wedge pressure (PCWP), with a mean value indicated around 38 mmHg. Bottom panels display digital telemetry data including a plethysmographic oxygen saturation (SpO2) of 93% and a respiratory rate of 16 inspirations per minute (ipm). This tracing is used in clinical cardiology and pulmonology to evaluate pulmonary vascular resistance and hemodynamic response in patients with systemic sclerosis-associated pulmonary arterial hypertension.

Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Searching Images

pulmonary hypertension pathology plexiform lesion vascular remodeling

This clinical photograph displays a gross pathological specimen of an open pulmonary artery. The luminal surface of the vessel exhibits significant morphological alterations, characterized by multiple raised, yellowish intimal plaques consistent with atheroma. These features are a classic hallmark of chronic pulmonary hypertension, which in this clinical context is associated with Eisenmenger syndrome—a condition where long-standing left-to-right congenital heart shunts cause pulmonary vascular remodeling. The presence of atherosclerotic-like changes in the typically low-pressure pulmonary circuit indicates severe, prolonged elevation in pulmonary arterial pressure. The image serves as an educational tool for identifying macroscopic signs of vascular pathology in the setting of advanced congenital heart disease and pulmonary hypertensive vascular disease.

This clinical photograph displays a gross pathological specimen of an open pulmonary artery. The luminal surface of the vessel exhibits significant morphological alterations, characterized by multiple raised, yellowish intimal plaques consistent with atheroma. These features are a classic hallmark of chronic pulmonary hypertension, which in this clinical context is associated with Eisenmenger syndrome—a condition where long-standing left-to-right congenital heart shunts cause pulmonary vascular remodeling. The presence of atherosclerotic-like changes in the typically low-pressure pulmonary circuit indicates severe, prolonged elevation in pulmonary arterial pressure. The image serves as an educational tool for identifying macroscopic signs of vascular pathology in the setting of advanced congenital heart disease and pulmonary hypertensive vascular disease.

This diagnostic image consists of two panels showing a thoracic contrast-enhanced computed tomography (CT) scan in axial (left) and coronal (right) views. A red arrow in both views points to a prominent, low-attenuation space-occupying lesion located within the right pulmonary artery, extending toward the hilum. This finding is characteristic of a central pulmonary thrombus or embolism, appearing as a filling defect that obstructs the contrast-filled vessel lumen. Additional clinical findings include a large right-sided pleural effusion, visible as a crescentic fluid collection in the posterior-dependent portion of the right hemithorax on the axial view. The heart appears enlarged, consistent with cardiomegaly and potential right heart strain associated with chronic thromboembolic pulmonary hypertension (CTEPH). The image serves as an educational example of central pulmonary vascular pathology and its secondary effects on the thoracic cavity, such as pleural effusion and cardiac remodeling.

This diagnostic image consists of two panels showing a thoracic contrast-enhanced computed tomography (CT) scan in axial (left) and coronal (right) views. A red arrow in both views points to a prominent, low-attenuation space-occupying lesion located within the right pulmonary artery, extending toward the hilum. This finding is characteristic of a central pulmonary thrombus or embolism, appearing as a filling defect that obstructs the contrast-filled vessel lumen. Additional clinical findings include a large right-sided pleural effusion, visible as a crescentic fluid collection in the posterior-dependent portion of the right hemithorax on the axial view. The heart appears enlarged, consistent with cardiomegaly and potential right heart strain associated with chronic thromboembolic pulmonary hypertension (CTEPH). The image serves as an educational example of central pulmonary vascular pathology and its secondary effects on the thoracic cavity, such as pleural effusion and cardiac remodeling.

Reading File
Reading File
Now I have comprehensive information to construct a thorough case discussion on pulmonary hypertension.

Pulmonary Hypertension - Case Study Discussion

Definition & Hemodynamic Criteria

Pulmonary hypertension (PH) is defined as mean pulmonary artery pressure (mPAP) > 20 mmHg at rest, measured by right heart catheterization (RHC) - revised downward from the old threshold of 25 mmHg at the 6th World Symposium on Pulmonary Hypertension (WSPH).
Hemodynamic subtypes (6th WSPH):
SubtypemPAPPCWPPVRWHO Groups
Normal14 ± 3.3 mmHg8 ± 2.9 mmHg0.93 ± 0.38 WU-
Precapillary PH>20 mmHg≤15 mmHg≥3 WU1, 3, 4, 5
Isolated postcapillary PH>20 mmHg>15 mmHg<3 WU2, 5
Combined pre+postcapillary PH>20 mmHg>15 mmHg≥3 WU2, 5
  • Murray & Nadel's Textbook of Respiratory Medicine, p.1893

WHO Classification (6th WSPH - Updated)

GroupCategoryKey Causes
Group 1 - PAHPulmonary arterial hypertensionIdiopathic (~50%), heritable (BMPR2 mutation), CTD-associated (scleroderma ~25%), HIV, drugs (methamphetamine, dasatinib), portal HTN, congenital heart disease
Group 1.5 (new)Long-term CCB respondersSubset of PAH who vasoreact
Group 1.6 (new)PVOD/PCH involvementPulmonary veno-occlusive disease
Group 2Left heart diseaseHFrEF, HFpEF, valvular disease, mitral stenosis
Group 3Lung disease/HypoxiaCOPD, ILD, sleep-disordered breathing, high altitude
Group 4Chronic thromboembolic (CTEPH)Post-PE (75% have prior PE), ~4% of PE patients develop CTEPH
Group 5Unclear/multifactorialSarcoidosis, metabolic disorders, hematologic conditions
  • Fuster and Hurst's The Heart, 15th Ed., Table 57-4

Pathogenesis

General Mechanisms (by group)

  • Hypoxic disease (Group 3): Obliteration of alveolar capillaries → increased PVR
  • Left heart disease (Group 2): Elevated left atrial/pulmonary venous pressure transmitted back to pulmonary arteries (e.g., mitral stenosis)
  • CTEPH (Group 4): Recurrent emboli reduce cross-sectional area of pulmonary vascular bed → increased PVR
  • Autoimmune (Group 1): Vascular inflammation and remodeling (especially systemic sclerosis)

Idiopathic/Familial PAH - Molecular Mechanism

  • BMPR2 gene mutation (bone morphogenetic protein receptor type 2) - found in 75% of familial cases and 25% of sporadic cases
  • BMPR2 is a TGF-β receptor superfamily member regulating endothelial and smooth muscle cell apoptosis, proliferation, and differentiation
  • Haploinsufficiency leads to endothelial dysfunction and vascular smooth muscle proliferation
  • A "two-hit" model is proposed: genetic susceptibility + additional environmental/genetic trigger
  • Only 10-20% of BMPR2 mutation carriers develop overt disease
BMPR2 pathway and pathogenesis of idiopathic pulmonary hypertension
Fig. 15.24 - Pathogenesis of primary (idiopathic) pulmonary hypertension showing BMPR2 pathway (Robbins Pathologic Basis of Disease)
  • Robbins, Cotran & Kumar Pathologic Basis of Disease, p.657

Morphology / Pathology

All forms share:
  • Medial hypertrophy of pulmonary muscular and elastic arteries
  • Right ventricular hypertrophy (cor pulmonale)
Progressive vascular changes:
  1. Large vessel - atherosclerosis-like intimal plaques (in severe/chronic cases)
  2. Arterioles (40-300 μm) - marked medial hypertrophy + intimal fibrosis → near-complete luminal obliteration (pinpoint channels)
  3. Plexiform lesions (hallmark of advanced Group 1 PAH) - tuft of capillary formations forming a network spanning dilated thin-walled small arteries
Plexiform lesions are most prominent in: idiopathic/familial PAH (Group 1), congenital heart disease with left-to-right shunts (Group 2), and HIV/drug-related PAH (Group 1).
Gross pathology of pulmonary artery in chronic pulmonary hypertension (Eisenmenger syndrome)
Gross pathology of pulmonary artery showing atheroma-like intimal plaques in chronic pulmonary hypertension (Eisenmenger syndrome)

Clinical Features

Who is affected: Idiopathic PAH predominantly affects females aged 20-40 years
SymptomNotes
Dyspnea on exertionMost common presenting complaint
FatigueEarly and prominent
Chest pain (anginal type)From RV ischemia
SyncopeFrom fixed low cardiac output, especially on exertion
Peripheral edemaLate sign of RV failure
CyanosisAdvanced disease
Signs become evident only in advanced disease - hence late diagnosis is common.
Prognosis without treatment: Death from decompensated cor pulmonale (often with superimposed thromboembolism and pneumonia) within 2-5 years in 80% of patients with idiopathic disease.

Diagnostic Workup

Step-by-Step Approach

  1. Clinical suspicion - unexplained exertional dyspnea, signs of RV strain
  2. ECG - RV strain pattern: right axis deviation, RBBB, P pulmonale
  3. Echocardiography - screening tool; estimates PASP via TR jet; RV hypertrophy/dilation, septal flattening ("D-sign")
  4. HRCT chest - lung parenchymal disease (Group 3), mosaic attenuation
  5. V/Q scan - essential to rule out CTEPH (Group 4) - mismatched segmental defects
  6. Right Heart Catheterization (RHC) - GOLD STANDARD for diagnosis and hemodynamic characterization
Right heart catheterization showing elevated pulmonary artery pressures (PA 68/24 mmHg) in SSc-PAH
RHC pressure tracing: PA pressure 68/24 (38) mmHg in a patient with systemic sclerosis-associated PAH
  1. Vasoreactivity testing (during RHC with IV adenosine or inhaled NO) - positive response: fall in mPAP ≥10 mmHg to ≤40 mmHg → qualifies for CCB therapy (Group 1.5)
  2. Additional workup: ANA, anti-Scl-70, HIV serology, LFTs (portal HTN), sleep study, 6-minute walk test

Management

General Principles

  • Treat the underlying cause in Groups 2, 3, 4, 5
  • Group 1 (PAH) has specific vasodilator therapies

Non-Pharmacological

  • Supplemental O2 (keep SpO2 > 91%)
  • Supervised exercise/rehabilitation
  • Diuretics for RV volume overload
  • Anticoagulation (especially CTEPH and idiopathic PAH)
  • Avoid pregnancy (mortality up to 30%)

Pharmacological - 3 Key Pathways for Group 1 PAH

PathwayDrug ClassAgents
Prostacyclin pathwayProstanoidsEpoprostenol (IV - most potent), Treprostinil, Iloprost
Endothelin pathwayERA (endothelin receptor antagonists)Bosentan, Ambrisentan, Macitentan
NO/cGMP pathwayPDE-5 inhibitorsSildenafil, Tadalafil
sGC stimulatorRiociguat
ERAs (bosentan, ambrisentan) are teratogenic - avoid in pregnancy. PDE-5 inhibitors and prostanoids are preferred in pregnant patients despite fetotoxicity risk if benefit outweighs risk.
  • Rosen's Emergency Medicine, p.802

CTEPH (Group 4) - Special Treatment

  • Pulmonary thromboendarterectomy (PTE) - potentially curative surgical option
  • Balloon pulmonary angioplasty (BPA) - for inoperable patients
  • Riociguat - approved specifically for inoperable/persistent CTEPH
CTEPH: Right heart catheterization hemodynamics and digital subtraction angiography showing pruned vasculature
CTEPH (Group 4): RHC hemodynamics (mPAP elevated, PCWP normal = precapillary) and DSA showing segmental stenoses and pruned vasculature

Surgical / Advanced

  • Lung transplantation - definitive treatment for refractory disease
  • Atrial septostomy - palliative in selected refractory cases

Recent Evidence (2024-2026)


Key Exam Points Summary

PointAnswer
Diagnostic gold standardRight heart catheterization (RHC)
mPAP threshold for PH (6th WSPH)>20 mmHg (previously 25 mmHg)
Most common PAH subtypeIdiopathic (~50% of Group 1)
Gene mutated in familial PAHBMPR2 (75% familial, 25% sporadic)
Hallmark histology lesionPlexiform lesion
Demographic of idiopathic PAHYoung women, 20-40 years
Only potentially curable formCTEPH (Group 4) - via PTE surgery
Contraindicated in PHPregnancy (mortality 30%); ERAs in pregnancy (teratogenic)
Drug not to use in non-PAH PHPAH-specific therapies worsen Group 2 disease
RV failure + PH =Cor pulmonale

Sources: Murray & Nadel's Textbook of Respiratory Medicine (p.1893), Robbins, Cotran & Kumar Pathologic Basis of Disease (p.657-658), Fuster and Hurst's The Heart 15th Ed., Rosen's Emergency Medicine
This is a shared conversation. Sign in to Orris to start your own chat.